According to the findings of clinical trials, both immunosuppression (IL-1 and IL-6 inhibitors) and immunomodulation (interferon alpha (IFN-α) and interferon beta (IFN-β)) and convalescent plasma therapy have been proposed as an effective treatment only in severe or critical COVID-19 conditions who require respiratory support and ventilation. Here, IL1B is linked to COVID-19.